Covid-19 manufacturing roundup: Indian manufacturer waives vaccine protections for migrants; EMA gives go-ahead for French J&J production site
Amid fears that millions of migrants may not have access to Covid-19 vaccines from Covax following liability fears, the Serum Institute of India has announced that it will waive its protection from legal liabilities for any AstraZeneca-Oxford doses it provides to the program, Reuters reported Wednesday.
Covishield can now be allocated to the Covax Humanitarian Buffer, a program designed to ensure that the most vulnerable portions of populations, such as conflict zones or humanitarian settings that are not able to be reached by government vaccination campaigns, are not left behind. Gavi sees it most effective in areas that have been impacted by state failure or areas controlled by groups that are not the government. Asylum seekers, refugees, detainees, and people who are stateless are all eligible.
Many manufacturers require protection from any side effects. That is not able to be guaranteed if there is no government.
The AstraZeneca shot is right now the main vaccine supplied to Covax. If all goes according to plan, the Pfizer-BioNTech jabs will take over that crown in 2022, Reuters said.
EMA approves new French site for J&J vaccine, approves Spain scale-up
A site in Marcy-l’Étoile, France has been given the OK by the EMA’s human medicines committee to manufacture the J&J Covid-19 vaccine.
The site, owned by Sanofi, will manufacture the finished product. It will support the continued supply of the vaccine, the agency said.
An Andover, MA site operated by Wyeth BioPharma has also been given the OK to up the production of the active substance for Pfizer-BioNTech’s Comirnaty. That will help support the supply for the EU. A Madrid, Spain site operated by Rovi will also be permitted a 50% scale-up of batch size for the finished product of Moderna’s Spikevax, and is allowed a second fill-finish line. These changes are expected to allow the production of another 25 million doses each month to the EU, and Covax.
Editor’s Note: For more news and exclusive coverage from the manufacturing beat, subscribe to the Endpoints Manufacturing weekly report in your reader profile.